Levemir Penfill

Insulin detemir, the active ingredient in Levemir Penfill, is an insulin analog presented as a pre‑filled pen solution for subcutaneous injection. It delivers long‑acting basal insulin to help regulate blood glucose in adults and children with type 1 or type 2 diabetes mellitus. Its prolonged duration of action reduces the need for multiple daily injections and provides a stable insulin level throughout the day.

GNH USA supplies Levemir Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity during global distribution.

Levemir Penfill (insulin detemir) provides basal insulin therapy for diabetes mellitus.

- Type 1 diabetes mellitus: maintains basal glucose control and reduces hyperglycaemic episodes. - Type 2 diabetes mellitus: complements oral agents or other insulin regimens to achieve fasting glucose targets.

Levemir Penfill may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypoglycaemia: low blood‑sugar episodes, especially if meals are missed or dose is excessive. - Injection site reactions: redness, swelling or itching at the injection site. - Weight gain: modest increase due to improved glucose utilisation. - Lipodystrophy: localized changes in fat tissue with repeated injections. - Edema: mild fluid retention, particularly in the lower extremities. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe hypoglycaemia: profound low blood glucose requiring assistance. - Anaphylactic reaction: rare systemic allergic response with rash, breathing difficulty. - Allergic dermatitis: severe skin reaction at injection sites. - Hypokalemia: low potassium levels in rare cases. - Acute insulin allergy: immediate hypersensitivity requiring medical attention. - Serum insulin antibodies: formation of antibodies that may alter insulin action.

Before using Levemir Penfill, consider the following safety measures.

- Blood‑glucose monitoring: check glucose levels regularly to adjust dose as needed. - Renal or hepatic impairment: dose may require adjustment; monitor closely. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy and lactation: use only if benefits outweigh risks; consult prescriber. - Patient education: ensure understanding of hypoglycaemia signs and management. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Penfill can interact with other medicines, affecting glucose control.

Major Interactions (Avoid): - Concomitant use of other rapid‑acting insulins: may cause severe hypoglycaemia. - Beta‑blockers: can mask hypoglycaemia symptoms, complicating detection.

Moderate Interactions (Monitor Closely): - Sulfonylureas or meglitinides: increase risk of hypoglycaemia; dose adjustments may be needed. - Corticosteroids: may raise glucose requirements, necessitating higher insulin doses. - Thiazide diuretics: can impair glucose tolerance, requiring closer monitoring. - ACE inhibitors: may potentiate insulin’s glucose‑lowering effect in some patients.